63,866 Shares in Kura Oncology, Inc. (NASDAQ:KURA) Purchased by Nebula Research & Development LLC

Nebula Research & Development LLC purchased a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 63,866 shares of the company's stock, valued at approximately $556,000. Nebula Research & Development LLC owned 0.08% of Kura Oncology at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Marshall Wace LLP purchased a new position in shares of Kura Oncology in the fourth quarter valued at $8,265,000. Vanguard Group Inc. lifted its holdings in shares of Kura Oncology by 14.6% in the fourth quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock worth $41,973,000 after buying an additional 615,211 shares in the last quarter. Trexquant Investment LP boosted its position in shares of Kura Oncology by 867.8% in the fourth quarter. Trexquant Investment LP now owns 566,945 shares of the company's stock valued at $4,938,000 after acquiring an additional 508,362 shares during the period. Renaissance Technologies LLC grew its stake in Kura Oncology by 463.4% during the fourth quarter. Renaissance Technologies LLC now owns 597,810 shares of the company's stock valued at $5,207,000 after acquiring an additional 491,700 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Kura Oncology by 35.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,425,960 shares of the company's stock worth $12,419,000 after acquiring an additional 372,196 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Barclays dropped their price objective on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research note on Friday. Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. StockNews.com lowered shares of Kura Oncology from a "buy" rating to a "hold" rating in a research report on Friday. HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Kura Oncology in a research report on Monday, April 28th. Finally, Scotiabank lowered their price target on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research note on Wednesday, January 8th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.89.

Kura Oncology Trading Down 0.3 %

Shares of KURA traded down $0.02 during trading hours on Friday, reaching $6.47. 1,635,415 shares of the company traded hands, compared to its average volume of 1,157,723. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $23.48. The company's fifty day moving average price is $6.73 and its two-hundred day moving average price is $9.64. The company has a market capitalization of $522.63 million, a price-to-earnings ratio of -2.74 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million during the quarter, compared to analyst estimates of $39.08 million. Equities research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.